Your institution may have access to this item. Find your institution then sign in to continue.
Title
DISCOVERY AND DEVELOPMENT OF BEVACIZUMAB, AN ANTI-VEGF ANTIBODY FOR TREATING CANCER.
Abstract
Discusses the discovery and development of bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody for treating cancer. Recognition of VEGF as an essential regulator of normal and abnormal blood vessel growth; U.S. Food and Drug Administration's approval of bevacizumab as a first-line therapy for metastatic colorectal cancer; Validation of the idea that VEGF is a key mediator of tumor angiogenesis.
Publication
Nature Reviews Drug Discovery, 2004, Vol 3, Issue 5, p391